Lasmiditan | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
Lasmiditan | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | |
Lasmiditan | hsa00500 | Starch and sucrose metabolism | 2.61E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
Lasmiditan | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | |
Lasmiditan | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
Lasmiditan | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.17E-02 | 3 | O95363, P14868, Q15046 | FARS2, DARS, KARS | More | |
Lasmiditan | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
Lasmiditan | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
Lasmiditan | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | |
Lasmiditan | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | |
Lasmiditan | hsa04060 | Cytokine-cytokine receptor interaction | 4.71E-02 | 2 | P78552, O75509 | IL13RA1, TNFRSF21 | More | |
Lasmiditan | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | |
Lasmiditan | hsa04072 | Phospholipase D signaling pathway | 9.70E-03 | 2 | Q92529, Q14344 | SHC3, GNA13 | More | |
Lasmiditan | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
Lasmiditan | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
Lasmiditan | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
Lasmiditan | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
Lasmiditan | hsa04610 | Complement and coagulation cascades | 2.78E-03 | 1 | P0C0L4 | C4A | More | |
Lasmiditan | hsa04612 | Antigen processing and presentation | 9.45E-05 | 9 | P13765, P48382, Q14953, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | |
Lasmiditan | hsa04650 | Natural killer cell mediated cytotoxicity | 5.07E-05 | 10 | P01375, P78314, O60880, P20963, Q13241, P26718, O75015, P26717, Q14953, P26715 | TNF, SH3BP2, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | |
Lasmiditan | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
Lasmiditan | hsa04660 | T cell receptor signaling pathway | 1.81E-02 | 8 | O95267, Q08881, P20963, P09693, P01732, Q13191, Q16539, P49841 | RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, MAPK14, GSK3B | More | |
Lasmiditan | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
Lasmiditan | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
Lasmiditan | hsa04730 | Long-term depression | 3.52E-02 | 1 | Q14344 | GNA13 | More | |
Lasmiditan | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
Lasmiditan | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
Lasmiditan | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
Lasmiditan | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
Lasmiditan | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
Lasmiditan | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
Lasmiditan | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | |
Lasmiditan | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Lasmiditan | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.38E-02 | 1 | P48048 | KCNJ1 | More | |
Lasmiditan | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
Lasmiditan | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
Lasmiditan | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | |
Lasmiditan | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
Lasmiditan | hsa05144 | Malaria | 1.84E-03 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | |
Lasmiditan | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
Lasmiditan | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
Lasmiditan | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
Lasmiditan | hsa05225 | Hepatocellular carcinoma | 1.85E-02 | 2 | Q92529, P51531 | SHC3, SMARCA2 | More | |
Lasmiditan | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
Lasmiditan | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Lasmiditan | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |